In corroboration, loss-of-function of G9a in vitro and pharmacological inhibition in vivo; or utilization of BMDMs derived from Sirt6−/− mice or in vivo infection in haplo-insufficient Sirt6−/+ mice; hampered host cholesterol accumulation and restricted Mtb burden. This evidence concerns the gene SIRT6 and infection.